Moshe Aftalion Selected Research

Ricin

11/2021	Intramuscular Exposure to a Lethal Dose of Ricin Toxin Leads to Endothelial Glycocalyx Shedding and Microvascular Flow Abnormality in Mice and Swine.
1/2021	Mice with induced pulmonary morbidities display severe lung inflammation and mortality following exposure to SARS-CoV-2.
1/2020	Post-Exposure Anti-Ricin Treatment Protects Swine Against Lethal Systemic and Pulmonary Exposures.
1/2019	Intramuscular Ricin Poisoning of Mice Leads to Widespread Damage in the Heart, Spleen, and Bone Marrow.
11/2017	Total Body Irradiation Mitigates Inflammation and Extends the Therapeutic Time Window for Anti-Ricin Antibody Treatment against Pulmonary Ricinosis in Mice.
12/2016	Potent Antiedematous and Protective Effects of Ciprofloxacin in Pulmonary Ricinosis.
1/2014	Antibody/doxycycline combined therapy for pulmonary ricinosis: Attenuation of inflammation improves survival of ricin-intoxicated mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Moshe Aftalion Research Topics

Disease

17	Infections 04/2022 - 05/2015
17	Plague (Bubonic Plague) 01/2022 - 02/2004
7	COVID-19 01/2022 - 01/2021
3	Poisoning 11/2021 - 01/2019
3	Disease Progression 10/2020 - 01/2013
2	Hemorrhage 11/2021 - 01/2019
2	Bacterial Infections (Bacterial Infection) 01/2021 - 01/2012
2	Virus Diseases (Viral Diseases) 01/2021 - 11/2020
2	Respiratory Insufficiency (Respiratory Failure) 11/2017 - 01/2014
2	Inflammation (Inflammations) 11/2017 - 01/2014
1	Body Weight (Weight, Body) 01/2021
1	Acute Lung Injury 01/2021
1	Human Influenza (Influenza) 11/2020
1	Necrosis 01/2019
1	Thrombocytopenia (Thrombopenia) 01/2019
1	Cystic Fibrosis (Mucoviscidosis) 01/2018
1	Leukopenia 11/2017
1	Edema (Dropsy) 12/2016
1	Lung Injury 12/2016

Drug/Important Bio-Agent (IBA)

9	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 01/2007
7	RicinIBA 11/2021 - 01/2014
7	VaccinesIBA 01/2021 - 09/2009
4	Neutralizing AntibodiesIBA 04/2022 - 05/2021
3	Monoclonal AntibodiesIBA 11/2021 - 01/2021
2	AntibodiesIBA 11/2021 - 01/2019
2	Angiotensin-Converting Enzyme 2IBA 01/2021 - 01/2021
2	CollagenIBA 11/2020 - 01/2019
2	Doxycycline (Periostat)FDA LinkGeneric 11/2020 - 01/2014
2	Ciprofloxacin (Cipro)FDA LinkGeneric 11/2020 - 12/2016
2	IronIBA 01/2019 - 01/2017
2	AntigensIBA 01/2019 - 01/2018
2	Lipoproteins (Lipoprotein)IBA 01/2019 - 09/2009
2	Virulence Factors (Pathogenicity Factors)IBA 01/2018 - 09/2009
2	Proteins (Proteins, Gene)FDA Link 01/2018 - 05/2015
2	CytokinesIBA 12/2016 - 01/2012
1	PhosphatidylglycerolsIBA 01/2022
1	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 01/2022
1	ClathrinIBA 01/2022
1	Heparitin Sulfate (Heparan Sulfate)IBA 01/2022
1	Bacterial RNAIBA 10/2021
1	RNA (Ribonucleic Acid)IBA 10/2021
1	Bleomycin (Blenoxane)FDA LinkGeneric 01/2021
1	Lipid NanoparticlesIBA 01/2021
1	mRNA VaccinesIBA 01/2021
1	Subgenomic RNAIBA 01/2021
1	AgarIBA 01/2021
1	Laminin (Merosin)IBA 11/2020
1	Metalloproteases (Metalloproteinases)IBA 11/2020
1	Indicators and Reagents (Reagents)IBA 10/2020
1	AntitoxinsIBA 01/2020
1	Twin-Arginine-Translocation SystemIBA 01/2019
1	Fibrinogen (Factor I)FDA Link 01/2019
1	EnzymesIBA 01/2019
1	Gentamicins (Gentamicin)FDA LinkGeneric 01/2018
1	Tobramycin (Nebcin)FDA LinkGeneric 01/2018
1	AminoglycosidesIBA 01/2018
1	Pharmaceutical PreparationsIBA 01/2018
1	ProteomeIBA 10/2017
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2016
1	Chemotactic FactorsIBA 05/2015
1	Messenger RNA (mRNA)IBA 05/2015
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 05/2015
1	ChemokinesIBA 01/2012
1	Attenuated VaccinesIBA 02/2004

Therapy/Procedure

12	Therapeutics 01/2022 - 09/2011
2	Phage Therapy 01/2022 - 01/2021